62 results about "Gallbladder cancer" patented technology

The invention relates to an ERBB signal pathway mutation targeted sequencing method for the prognosis evaluation of gallbladder carcinoma and provides an application of an ERBB signal pathway mutation targeted sequencing reagent / kit for gallbladder carcinoma patients. In the invention, the whole-genome exon technology is adopted for performing mutation target sequencing of the ERBB signal pathway of a gallbladder carcinoma patient; and in combination with the pathological clinical data of the gallbladder carcinoma patient, the Kaplan-Meier survival curve analysis indicates that the lifetime of the patient after operation is closely related to the gene mutation of the ERBB signal pathway, and the multiple-factor analysis of Cox risk regression model indicates that the gene mutation of the ERBB signal pathway can serve as an independent prognosis factor of gallbladder carcinoma. The prompt of screening the ERBB signal pathway related gene mutation of the gallbladder carcinoma cancer is favorable to the gene-level diagnosis and parting of gallbladder carcinoma, the establishment of therapeutic target, the prognosis analysis and the like.

Provided is an antibody effective for treatment and / or prevention of gallbladder cancer. A pharmaceutical composition for treatment and / or prevention of gallbladder cancer contains as an active ingredient an antibody or a fragment thereof having immunological reactivity with a CAPRIN-1 protein or a fragment thereof comprising at least seven consecutive amino acid residues of the amino acid sequence of the protein.

The invention relates to an anti-cancer agent containing α-chain protein (α-fragment) of HGF (hepatocyte growth factor) as an active ingredient. The active ingredient of α-fragment has a specific suppressing effect on invasion and metastasis of cancer cells such as gallbladder cancer, lung cancer and other, which are highly metastatic and result in a high mortality. Therefore, the agent of the invention is used in treatment and prevention of cancer as an anti-cancer agent, and is extremely useful clinically.

The invention relates to a method for establishing a prediction model for survival benefit of a gallbladder cancer patient after chemoradiotherapy. The method comprises the steps of acquiring clinical and pathological data of the gallbladder cancer patient; dividing the acquired data into a plurality of groups of data according to the TNM stages, and respectively judging whether the patient in each stage is benefited from adjuvant therapy or not; dividing the data corresponding to the TNM stages into a modeling group and an internal verification group; analyzing the prediction capability of clinical and pathological variables of the modeling group data on the total survival time OS through a single-factor COX risk scale model, and screening risk factors which significantly influence the total survival time OS of the patient in the modeling group; incorporating the screened risk factors into a multi-factor COX risk scale model for analysis, and screening out influence variables significantly influencing the total survival time OS of the patient; according to the obtained influence variables, drawing a column graph used for predicting the total survival time OS, and obtaining a prediction model; and verifying the model. Compared with the prior art, the method has the advantages of providing credible prediction and analysis results for the GBC patient, being simple and convenient to operate and the like.

The present invention provides a combination therapy for effectively treating and / or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.

The present invention provides antibodies, which can be used as a therapeutic agent for treating and / or preventing diseases associated with cells expressing CLD18, including tumor-related diseases, such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, Liver, head and neck, and gallbladder cancers.

Provided is an antibody effective for treatment and / or prevention of gallbladder cancer. A pharmaceutical composition for treatment and / or prevention of gallbladder cancer contains as an active ingredient an antibody or a fragment thereof having immunological reactivity with a CAPRIN-1 protein or a fragment thereof comprising at least seven consecutive amino acid residues of the amino acid sequence of the protein.

The invention discloses a newly discovered cancer promoting effect of DDX24 helicase, a method for realizing a cancer inhibition effect through point mutation and application of the DDX24 helicase. The contents of the invention comprise: 1, high expression of wild type DDX24 has significant correlation with tumor growth, and the growth of tumors can be promoted through high expression of the wildtype DDX24; 2, different from the mechanism of the pathogenic gene DDX24 for familial vascular malformation, DDX24 point mutation including K11E or E271K obviously inhibits the growth of tumors; 3, based on the new function and induced point mutation of DDX24 provided in the invention, a novel targeted therapy method can be provided for treatment of latent and refractory tumors, and a new thoughtcan also be provided for preparation of tumor-related vaccines; and 4, application of 1-3 described above is provided. The point mutation can be used for treating solid tumors including, but not limited to, squamous cell carcinoma of the head and the neck, esophageal cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, skin melanoma, lymphoma, adenoma, thoracic adenoma, lung cancer, colorectal cancer, gallbladder cancer, kidney cancer, bladder cancer, prostate cancer, breast cancer, ovarian cancer, endometrial cancer, cervical cancer, nasopharyngeal cancer, bone cancer andmalignant myoma.

The invention discloses a liver and bile cancer cell postoperative monitor based on big data, which comprises a detection device being a special earphone, wherein the detection device is electrically connected with a data transmission device, the data transmission device is electrically connected with a processor, and the processor is connected with a medical system and a cloud server; thus, the early warning is carried out on diseases through the medical system and the cloud server. The invention further discloses a using method of the liver and bile cancer cell postoperative monitor based on the big data, which comprises the following steps: S1, searching information of a to-be-detected person through the to-be-detected person, and then preparing related information of the to-be-detected person for research. The postoperative monitor is reasonable in structure, neurons can be stimulated to generate chemical electric signals, and the disease state and degree of the human cell level are judged after analysis, so that postoperative treatment of liver and gallbladder cancer cells is facilitated.

The invention discloses a honey health preserving wine, which comprises the following raw materials and auxiliary materials: 3 g of honeybee pupae, 3 g of bee, 3 g of honey, 10 g of red date, 10 g ofChinese wolfberry, 5 g of millettia speciosa champ, 500 g of Baijiu with an alcoholicity of 62 DEG, and 10 g of longan. According to the present invention, leaching, extraction of the medicinal components of honey and bee venom and prepared fermentation with high-concentration Baijiu are performed, and finally the high-alcohol-concentration honey health preserving wine is obtained through the secondary fermentation; the honey health preserving wine has advantages of stable performance, good efficacy, golden color, unique fragrance and delicious taste, has effects of wind dampness removing, wind cold removing, blood pressure lowering, paralysis treating, impotence treating, prospermia treating, blood fat lowering, face nourishing, blood enriching and qi supplementing, contains the medicinalcomponents of bee venom, can be used for treating chronic bronchitis, can further be used for the assisted treatment of acquired immunodeficiency syndrome, lung cancer, gallbladder cancer and other cancers, can be used for coated treatment of psoriasis and eczema, and has significant treatment effects.

The present invention provides antibodies that can be used as therapeutic agents for the treatment and / or prevention of diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, Liver, head and neck and gallbladder cancers.

The invention relates to a traditional Chinese medicine composition for hepatological surgery department, in particular to a traditional Chinese medicine composition for use after gallbladder cancer surgery and a preparation method thereof. A pharmaceutical for oral administration is prepared from the following components in parts by mass: 3-5 parts of white rhizoma Et radix polygoni-cuspidatl, 5-10 parts of poria cocos, 5-8 parts of longan, 3-5 parts of rhodiola rosea, 3-5 parts of peperomia blanda, 5-8 parts of soybean, 3-5 parts of garden burnet, 3-5 parts of radix ophiopogonis, 3-5 parts of rhizoma panacis majoris, 5-8 parts of liquorice root, 5-8 parts of water chestnut hull, 3-5 parts of gynostemma pentaphyllum, 3-5 parts of loquat, 5-8 parts of Chinese Date, 5-8 parts of Chinese angelica, 5-8 parts of pilose antler and 5-8 parts of lucid ganoderma; a pharmaceutical for external use is prepared from the following components in parts by mass: 3-5 parts of chinaroot greenbrier, 5-8 parts of tangerine pith, 3-5 parts of catbrier, 5-8 parts of resina liquidambaris, 5-8 parts of plant soot, 5-8 parts of bletilla striata, 3-5 parts of radix cynanchi bungei, 3-5 parts of thyme and 3-5 parts of lignum dalbergiae odoriferae. According to the traditional Chinese medicine composition disclosed by the invention, the pharmaceutical for oral administration is cooperated with the pharmaceutical for external use to take effect; the pharmaceutical for oral administration has the advantages of tonifying qi, promoting blood circulation and detoxication, and can facilitate effect of the pharmaceutical for external use for stopping bleeding and promoting healing; and meanwhile the pharmaceutical for external use can stop bleeding and dredging collaterals, and can facilitate effect initiation of the pharmaceutical for oral administration.

The invention discloses gallbladder cancer diagnosis and prognosis judgment marker PIM1, and also discloses a gallbladder cancer diagnosis and prognosis judgment kit, which can be used for diagnosis, prediction, detection or screening of human gallbladder cancer cell proliferation, gallbladder cancer clinical stage or gallbladder cancer cancer patient prognosis. The invention also discloses the use of the PIM1 protein inhibitor in the preparation of anti-gallbladder cancer drugs. The present invention shows that PIM1 has very important significance in clinical practice, and may become a new generation of tumor biodiagnostic markers and molecular targets for tumor treatment, and opens up the research of new targets for gallbladder cancer mainly based on PIM1. Open up a new way for the development of new anti-tumor drugs.

The invention provides an usnea longifolia derivative and application thereof in preparation of a medicine for treating gallbladder cancer. The usnea longifolia derivative has a chemical name of 3, 6-diacetyl-2, 7, 9-trihydroxy-8, 9b-dimethyl-1 (9bH)-dibenzofuranone, has an effect of inhibiting activity of human gallbladder cancer cells and has a small toxic effect on normal cells. The compound can be independently used in the treatment of gallbladder cancer and can also be used in combination with other drugs. The inventor of the invention unexpectedly finds that the compound can achieve a better effect of inhibiting cholecystoma cancer cells when being combined with cisplatin and can effectively slow down the side effects generated by cisplatin. The medicine for treating the gallbladdercancer has great application potential.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.